Helsinki: The European Commission’s confirmation, delivered by Environment Commissioner Jessika Roswall at the European Parliament’s environment committee on 27 April 2026, that the planned full revision of the REACH Regulation will not be tabled as a legislative proposal during the current mandate has settled a debate that had absorbed industry and civil society attention for the better part of three years. The decision does not close the chemical policy file. It reframes it. The structural changes that the 2020 Chemicals Strategy for Sustainability promised, from the generic risk-management approach to a wholesale recasting of authorisation and restriction, will not arrive through co-decision. They will arrive, if at all, through the comitology and technical-amendment machinery that sits beneath the parent regulation, and through enforcement instruments that the Commission can deploy without parliamentary involvement.
The institutional logic behind the shelving is more political than legal. REACH carries an unusual cross-political-family sensitivity in the European Parliament. Environment, public health and consumer protection constituencies on the centre-left and green benches have pressed for faster restriction cycles, lower exposure thresholds and more aggressive treatment of substances of very high concern. Manufacturing constituencies on the centre-right and liberal benches, supported during the past two years by capitals with concentrated chemicals industries, have pushed for predictability, regulatory simplification and a reweighting of competitiveness against the precautionary baseline. The Letta report on the single market and the Draghi report on competitiveness gave the second camp rhetorical ammunition that the Commission was unwilling to spend political capital opposing in a co-decision file whose outcome would have remained unpredictable until the final trilogue.
What replaces the revision is a more tactical agenda. The endocrine-disruptor classification under the revised Classification, Labelling and Packaging Regulation has already begun to bite, with new substances placed on the market after 1 May 2025 required to be labelled under the new hazard classes and mixtures following from 1 May 2026. The European Chemicals Agency’s organisational restructuring on 9 February 2026 was timed to support the expanded technical workload that the targeted approach will generate. The agency’s ECHA CHEM database now publishes the endocrine-disruptor assessment list openly, replacing the older fragmented disclosures that industry and civil society alike found difficult to navigate. The PFAS universal restriction proposal, the most consequential single chemical file under active consideration, continues to move through the restriction procedure under Article 69 of REACH, with the regulatory committee scheduled to receive a refined version this year.
The enforcement dimension is where the most consequential changes are likely to land in the absence of a full revision. The Commission has signalled, through the 2025 enforcement report and the new Single Market Enforcement Agenda, that imported chemicals at the external border will receive intensified market surveillance. Customs cooperation under the European Union Customs Code, the implementation of the IT-supported notification system for hazardous substances and the alignment with the upcoming Customs Reform package will deliver a perceptible tightening of import controls without any new substantive obligation on EU producers. For non-EU manufacturers selling into the bloc through importers and only-representative arrangements, the practical effect of the targeted approach may exceed what a full revision would have delivered, because procedural friction translates into market-access cost more readily than substantive amendments.
For industry, the shelving removes a five-year overhang of regulatory uncertainty about authorisation lists, registration data quality requirements and the boundary between REACH and downstream sectoral legislation on cosmetics, pharmaceuticals and biocides. It does not remove the obligation to monitor a denser stream of technical amendments, restriction proposals and harmonised classification dossiers. The chemicals sector compliance teams that had structured themselves around the revision are being reorganised around what is in effect a regime of continuous targeted action rather than periodic legislative overhaul. The reallocation is straightforward for the largest registrants and disproportionately heavy for the small and mid-sized enterprises that the Commission’s simplification agenda was meant to relieve.
For environmental and health constituencies, the shelving is harder to absorb. The 2020 strategy promised a generic risk-management approach and an end to the assessment-by-assessment grind that had left several thousand substances of concern unaddressed for more than a decade. The targeted path that has replaced it will not deliver that systemic shift on the timeline the strategy envisaged. The Commission’s argument that comitology can absorb the substantive ambition of the revision will be tested through the next eighteen months, as the first wave of post-shelving restriction proposals reaches the regulatory committee and the calibration between technical and political control becomes visible.
